ClinicalTrials.Veeva

Menu
O

Oncology Hematology Care, Inc. | Cincinnati, OH

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Carboplatin
Bevacizumab
Pembrolizumab
Docetaxel
Gemcitabine
Paclitaxel
Trastuzumab
Atezolizumab
Lenalidomide
Nivolumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

46 of 221 total trials

A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) (DeLLphi-301)

The main aim of this study is to:* evaluate safety and efficacy (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST 1.1\] by inves...

Active, not recruiting
Relapsed/Refractory Small Cell Lung Cancer
Drug: Tarlatamab

The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician...

Enrolling
Metastatic HER2-positive Breast Cancer
Drug: Trastuzumab
Drug: Gemcitabine

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with end...

Enrolling
Early Breast Cancer
Drug: Endocrine Therapy of Physician's Choice
Drug: Abemaciclib

This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance tr...

Active, not recruiting
FIGO Stage III-IV
Newly Diagnosed
Drug: Placebo Oral Tablet
Drug: Rucaparib

This is an open-label, multicenter, extension study. Patients who are receiving clinical benefit from atezolizumab monotherapy or atezolizumab in com...

Enrolling
Cancer
Drug: Emactuzumab
Drug: Niraparib

The main purpose of this study is to evaluate how safe and effective the study drug known as abemaciclib is in participants with lung cancer.

Active, not recruiting
Non Small Cell Lung Cancer
Drug: Erlotinib
Drug: Abemaciclib

The primary objective of this study is to compare belzutifan to everolimus with respect to progression-free survival (PFS) per Response Evaluation Cr...

Active, not recruiting
Carcinoma, Renal Cell
Drug: Everolimus
Drug: Belzutifan

This study will investigate the utility of biomarker-based triage for study participants with advanced non-small cell lung cancer (NSCLC) without pri...

Active, not recruiting
Advanced Non-Small Cell Lung Cancer
Drug: Quavonlimab
Biological: Favezelimab

The purpose of this study is to evaluate conversion rate to minimal residual disease (MRD) negativity following the addition of daratumumab to lenali...

Active, not recruiting
Multiple Myeloma
Drug: Lenalidomide
Drug: Daratumumab

The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer...

Active, not recruiting
Urothelial Cancer
Drug: Erdafitinib
Drug: Docetaxel

The purpose of this study is to evaluate the efficacy of erdafitinib in terms of overall response rate (ORR) in adult and pediatric participants with...

Active, not recruiting
Advanced Solid Tumor
Drug: Erdafitinib

This randomized, double-blind, placebo-controlled, two-arm study will assess the safety and efficacy of pertuzumab in addition to chemotherapy plus t...

Active, not recruiting
Breast Cancer
Drug: 5-Fluorouracil
Drug: Cyclophosphamide

The purpose of this study is to determine how participants with metastatic castration-resistant prostate cancer, and evidence of a homologous recombi...

Active, not recruiting
Metastatic Castration Resistant Prostate Cancer
Drug: Abiraterone acetate or Enzalutamide or Docetaxel
Drug: Rucaparib

This clinical trial is studying nonsquamous non-small cell lung cancer (NSCLC). Participants in this study must have cancer that has spread through t...

Enrolling
Carcinoma, Non-Small-Cell Lung
Drug: sigvotatug vedotin
Drug: docetaxel

This is a Phase 2 study to evaluate the clinical activity and safety of ZN-c3 (azenosertib) in adult women with recurrent or persistent uterine serou...

Enrolling
Uterine Serous Carcinoma
Drug: ZN-c3

The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing o...

Enrolling
Small Lymphocytic Lymphoma
Leukemia, Lymphocytic, Chronic, B-Cell
Drug: Venetoclax
Drug: Ibrutinib

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Classic Follicul...

Enrolling
Classic Follicular Lymphoma
Diffuse Large B-Cell Lymphoma
Drug: Epcoritamab

This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, b...

Enrolling
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Diagnostic Test: FoundationOne Liquid CDx Assay (F1LCDx)
Drug: Giredestrant

The study is designed to compare the tolerability of asciminib versus nilotinib for the treatment of newly diagnosed, previously untreated patients w...

Active, not recruiting
Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Drug: Nilotinib
Drug: Asciminib

This is a parallel, Phase 3, two-arm study for the treatment of newly diagnosed moderate or severe chronic GVHD.The study duration for a participant...

Enrolling
Chronic Graft Versus Host Disease
Drug: Prednisone
Drug: Prednisolone

Trial sponsors

S
Roche logo
Celgene logo
Lilly logo
Amgen logo
Bristol-Myers Squibb (BMS) logo
Genentech logo
Gilead Sciences logo
Incyte logo
Janssen (J&J Innovative Medicine) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems